Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers

被引:27
作者
Amsden, Guy W.
Gregory, Thomas B.
Michalak, Cheryl A.
Glue, Paul
Knirsch, Charles A.
机构
[1] Clin Res Div Bassett Healthcare, Cooperstown, NY 13326 USA
[2] Pfizer Inc, Clin Res & Dev, New York, NY USA
关键词
D O I
10.4269/ajtmh.2007.76.1153
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Azithromycin is a critical component of an integrated disease elimination program against trachoma. This study was conducted to evaluate whether azithromycin has a pharmacokinetic interaction with the combination of ivermectin and albendazole. Eighteen healthy volunteers were administered single doses of azithromycin, ivermectin/albendazole, and the combination of the three agents in random, crossover fashion. To assess the presence of interactions, test (combination) and reference (single dose) data were compared using an estimation approach. Compared with reference phases, the geometric mean values for the combination arm's azithromycin AUC(0-1) and C-max were increased approximately 13% and 20%, respectively, albendazole AUC(0-1) decreased by approximately 3% and C-max increased approximately 3%, and ivermectin AUC(0-1) and C-max were increased 31% and 27%, respectively. Albendazole sulfoxide AUC(0-1) and C-max were decreased approximately 16% and 14%, respectively. All treatments were well tolerated. The interactions for azithromycin and albendazole were minimal although the increase in ivermectin exposure requires further study.
引用
收藏
页码:1153 / 1157
页数:5
相关论文
共 26 条
[1]   COMPARISON OF THE EFFECTS OF THE NEW AZALIDE ANTIBIOTIC, AZITHROMYCIN, AND ERYTHROMYCIN ESTOLATE ON RAT-LIVER CYTOCHROME-P-450 [J].
AMACHER, DE ;
SCHOMAKER, SJ ;
RETSEMA, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) :1186-1190
[2]   Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects [J].
Amsden, GW ;
Nafziger, AN ;
Foulds, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) :163-165
[3]   Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers [J].
Amsden, GW ;
Gray, CL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (01) :61-66
[4]  
Amsden GW, 2000, J CLIN PHARMACOL, V40, P1522
[5]   The co-administration of ivermectin and albendazole safety, pharmacokinetics and efficacy against Onchocerca volvulus [J].
Awadzi, K ;
Edwards, G ;
Duke, BOL ;
Opoku, NO ;
Attah, SK ;
Addy, ET ;
Ardrey, AE ;
Quartey, BT .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2003, 97 (02) :165-178
[6]   Pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leucocytes and inflammatory vs non-inflammatory skin blisters in healthy volunteers [J].
Ballow, CH ;
Amsden, GW ;
Highet, VS ;
Forrest, A .
CLINICAL DRUG INVESTIGATION, 1998, 15 (02) :159-167
[7]   Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus [J].
Baraka, OZ ;
Mahmoud, BM ;
Marschke, CK ;
Geary, TG ;
Homeida, MMA ;
Williams, JF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (05) :407-410
[8]   Current trachoma treatment methodologies - Focus on advancements in drug therapy [J].
Chiu, LM ;
Amsden, GW .
DRUGS, 2002, 62 (18) :2573-2579
[9]  
DESPOMMIER DD, 2005, PARASITIC DIS, P143
[10]   THE RELATIVE SYSTEMIC AVAILABILITY OF INVERMECTIN AFTER ADMINISTRATION AS CAPSULE, TABLET, AND ORAL SOLUTION [J].
EDWARDS, G ;
DINGSDALE, A ;
HELSBY, N ;
ORME, MLE ;
BRECKENRIDGE, AM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (06) :681-684